Abstract
NAFLD is the most common liver disease worldwide but it is the potential evolution to cirrhosis and hepatocellular carcinoma (HCC) that makes NAFLD of such clinical importance. The current work provides an overview of the main mechanims and potential therapeutical insights involved in NAFLD, NASH, fibrosis and HCC progression.
Keywords: NAFLD, NASH, fibrosis, microbiota, bacterial translocation.
Current Pharmaceutical Design
Title:From NAFLD to NASH and HCC: Pathogenetic Mechanisms and Therapeutic Insights
Volume: 19 Issue: 29
Author(s): Samuele De Minicis, Chris Day and Gianluca Svegliati-Baroni
Affiliation:
Keywords: NAFLD, NASH, fibrosis, microbiota, bacterial translocation.
Abstract: NAFLD is the most common liver disease worldwide but it is the potential evolution to cirrhosis and hepatocellular carcinoma (HCC) that makes NAFLD of such clinical importance. The current work provides an overview of the main mechanims and potential therapeutical insights involved in NAFLD, NASH, fibrosis and HCC progression.
Export Options
About this article
Cite this article as:
De Minicis Samuele, Day Chris and Svegliati-Baroni Gianluca, From NAFLD to NASH and HCC: Pathogenetic Mechanisms and Therapeutic Insights, Current Pharmaceutical Design 2013; 19 (29) . https://dx.doi.org/10.2174/1381612811319290006
DOI https://dx.doi.org/10.2174/1381612811319290006 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Influence of Tumor Microenvironment on the Distribution and Elimination of Nano-formulations
Current Drug Metabolism New Use for Old Drugs? Prospective Targets of Chloroquines in Cancer Therapy
Current Drug Targets Targeting the Ubiquitin-Mediated Proteasome Degradation of p53 for Cancer Therapy
Current Pharmaceutical Design 5-Fluorouracil Loaded Orally Administered WGA-decorated Poly(lacticco- glycolic Acid) Nanoparticles for Treatment of Colorectal Cancer: <i>In Vivo</i> Evaluation
Current Nanomedicine Naturally Occurring and Synthetic Bioactive Molecules as Novel Non-Nucleoside HBV Inhibitors
Mini-Reviews in Medicinal Chemistry Multidrug Resistance Through the Spectacle of P-Glycoprotein
Current Cancer Drug Targets Gene Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Cell-in-cell phenomenon: A New Paradigm in Life Sciences.
Current Molecular Medicine Advancement and Strategies for the Development of Peptide-drug Conjugates: Pharmacokinetic Modulation, Role and Clinical Evidence against Cancer Management
Current Cancer Drug Targets Stem Cell Ageing and Apoptosis
Current Pharmaceutical Design Cullin-RING Ligases as Attractive Anti-cancer Targets
Current Pharmaceutical Design Palmitoylethanolamide in Homeostatic and Traumatic Central Nervous System Injuries
CNS & Neurological Disorders - Drug Targets Impact of Immunogenetic Polymorphisms in Bone Marrow Failure Syndromes
Mini-Reviews in Medicinal Chemistry Monoclonal Antibody Therapy in Haematological Malignancies
Current Clinical Pharmacology Prognostic Parameters in Myeloid Malignancies in a Historical Context – From Microscopy to Individualized Medicine
Current Drug Targets Heat Shock Proteins in Cancer: Signaling Pathways, Tumor Markers and Molecular Targets in Liver Malignancy
Protein & Peptide Letters Anti-CD20 Antibody in Primary Sjogren's Syndrome Managemen
Current Pharmaceutical Biotechnology Development of Patents and Clinical Trials on Regenerative Therapy: Gene Therapy
Recent Patents on Regenerative Medicine The PI3K/Akt Pathway as a Target in the Treatment of Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets